These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2132940)

  • 21. Epigenetic mechanisms of the carcinogenic effects of xenobiotics and in vitro methods of their detection.
    Hofmanová J; Machala M; Kozubík A
    Folia Biol (Praha); 2000; 46(5):165-73. PubMed ID: 11055794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans.
    Brändlein S; Pohle T; Ruoff N; Wozniak E; Müller-Hermelink HK; Vollmers HP
    Cancer Res; 2003 Nov; 63(22):7995-8005. PubMed ID: 14633732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Morphine affects the proliferation of tumour cells].
    Olsen P; Rasmussen M; Stefano GB; Tønnesen EK
    Ugeskr Laeger; 2004 Nov; 166(48):4347-50. PubMed ID: 15587623
    [No Abstract]   [Full Text] [Related]  

  • 24. Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation.
    Lincoln DT; Singal PK; Al-Banaw A
    Anticancer Res; 2007; 27(6B):4201-18. PubMed ID: 18225592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of gap junctional cell/cell communication in the control of proliferation and neoplastic transformation.
    Bertram JS
    Radiat Res; 1990 Sep; 123(3):252-6. PubMed ID: 2217721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
    Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contact interactions between cells that suppress neoplastic development: can they also explain metastatic dormancy?
    Rubin H
    Adv Cancer Res; 2008; 100():159-202. PubMed ID: 18620096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumour specific antigens associated with chemically induced tumours.
    Baldwin RW
    Rev Eur Etud Clin Biol; 1970; 15(6):593-8. PubMed ID: 4319386
    [No Abstract]   [Full Text] [Related]  

  • 29. Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk.
    Cabillic F; Bouet-Toussaint F; Toutirais O; Rioux-Leclercq N; Fergelot P; de la Pintière CT; Genetet N; Patard JJ; Catros-Quemener V
    Clin Exp Immunol; 2006 Dec; 146(3):518-23. PubMed ID: 17100773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct targeting of genetically modified tumour cells to Fc gammaRI triggers potent tumour cytotoxicity.
    Bevaart L; Goldstein J; Vitale L; Russoniello C; Treml J; Zhang J; Graziano RF; Leusen JH; van de Winkel JG; Keler T
    Br J Haematol; 2006 Feb; 132(3):317-25. PubMed ID: 16409296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD44: from adhesion molecules to signalling regulators.
    Ponta H; Sherman L; Herrlich PA
    Nat Rev Mol Cell Biol; 2003 Jan; 4(1):33-45. PubMed ID: 12511867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immunological processes and their morphological manifestations in the development of tumors].
    Ageev AK
    Arkh Patol; 1974; 36(6):72-80. PubMed ID: 4137423
    [No Abstract]   [Full Text] [Related]  

  • 33. Induction of various immune modulatory molecules in CD34(+) hematopoietic cells.
    Umland O; Heine H; Miehe M; Marienfeld K; Staubach KH; Ulmer AJ
    J Leukoc Biol; 2004 Apr; 75(4):671-9. PubMed ID: 14742640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Intercellular communications in cell differentiation and in hepatic carcinogenesis].
    Guguen-Guillouzo C; Corlu A; Loyer P; Baffet G; Gripon P
    Ann Gastroenterol Hepatol (Paris); 1994; 30(2):64-9. PubMed ID: 8210206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccination for treatment of tumors: a critical comment.
    Sedlacek HH
    Crit Rev Oncog; 1994; 5(6):555-87. PubMed ID: 8519811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Differentiation antigens in tumors: dependence on carcinogenesis mechanisms and progression (a hypothesis)].
    Abelev GI
    Mol Biol (Mosk); 2003; 37(1):4-11. PubMed ID: 12624942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell matrix adhesion-related proteins VLA-1 and VLA-2: regulation of expression on T cells.
    Hemler ME; Jacobson JG
    J Immunol; 1987 May; 138(9):2941-8. PubMed ID: 3106495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statins inhibit NK-cell cytotoxicity by interfering with LFA-1-mediated conjugate formation.
    Raemer PC; Kohl K; Watzl C
    Eur J Immunol; 2009 Jun; 39(6):1456-65. PubMed ID: 19424968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunology in the clinical practice. XVI. Paraneoplastic syndromes of the nervous system: pathogenesis and diagnosis].
    Smitt PA; de Leeuw B; Vecht CJ
    Ned Tijdschr Geneeskd; 1998 Jul; 142(29):1652-8. PubMed ID: 9763856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals.
    Robertson MJ; Cameron C; Lazo S; Cochran KJ; Voss SD; Ritz J
    Nat Immun; 1996-1997; 15(5):213-26. PubMed ID: 9390270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.